Enspryng (satralizumab) for Thyroid eye disease (TED)
The FDA is expected to decide on Enspryng for Thyroid eye disease (TED) by October 15, 2026, under a sBLA from Genentech (Roche).
What is being decided
Genentech (Roche) has a sBLA under FDA review for Enspryng (satralizumab) in Thyroid eye disease (TED). Priority review. Enspryng blocks the interleukin-6 receptor and is given as an under-the-skin injection, every 4 weeks in its approved NMOSD use, which would make it the first at-home subcutaneous treatment for thyroid eye disease, the autoimmune complication of Graves' disease that pushes the eyes forward and can cause double vision. In the Phase 3 SatraGO-2 trial, 53% of patients had their eye bulging (proptosis) improve by at least 2 mm at week 24 versus 23% on placebo; the twin SatraGO-1 trial showed 49% versus 31%, which did not reach statistical significance. Enspryng is already approved for NMOSD, and a separate application for MOGAD is due January 10, 2027.
Who this decision matters to
Thyroid eye disease (TED) is a rare autoimmune condition in which the immune system attacks the muscles and fat behind the eyes, causing bulging eyes, double vision, pain, and in severe cases vision loss. It most often occurs alongside Graves' disease. Two targeted IGF-1R therapies are now FDA approved, with pills and injections in late-stage trials.
Prevalence: About 16 in 100,000 women and 3 in 100,000 men diagnosed each year; up to half of people with Graves' disease develop some degree of TED. See our full Thyroid Eye Disease page for current treatments, recruiting trials, and community resources.
What each outcome would mean
An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.
A complete response letter would mean the FDA declined to approve in the application's current form. CRLs are often about manufacturing or data presentation rather than efficacy, and resubmission is common. Either way, this page updates with the outcome and what it means.
Where Thyroid Eye Disease treatment stands today
Two FDA-approved therapies now target IGF-1R, the receptor driving tissue expansion behind the eyes. Teprotumumab (Tepezza, approved January 2020) is given as 8 infusions over about 5 months. Veligrotug (Lumvoa, approved June 2026) is given as 5 infusions over 12 weeks and is the first therapy with label data covering both active and chronic TED. The pipeline is aimed at making treatment easier to take: elegrobart, a subcutaneous injection, posted positive Phase 3 results in active TED in 2026, and an oral pill (linsitinib) is in a Phase 3 trial. Another injectable antibody, lonigutamab, has no active trial listed on ClinicalTrials.gov, and its owner, Alumis, said in May 2026 that it would explore strategic alternatives for the program. IGF-1R blockers can affect hearing, so trials and treatment alike include hearing checks; mention any hearing changes to your care team promptly. An oculoplastic specialist or a neuro-ophthalmologist experienced in TED is the right doctor to ask about trial eligibility, which often depends on whether your disease is active or chronic.
Meanwhile, 93 Thyroid Eye Disease trials are recruiting
Whatever the FDA decides here, research on Thyroid Eye Disease does not stop. A few currently enrolling studies, US sites first:
Other drugs Trial Friend tracks for Thyroid Eye Disease
Get notified when new thyroid-eye-disease trials open or existing trials change status, add sites, or update eligibility.
Our coverage
Frequently asked questions
When will the FDA decide on Enspryng?
The FDA's target decision date (PDUFA date) for Enspryng in Thyroid eye disease (TED) is October 15, 2026, disclosed by Genentech (Roche). The agency can act before this date and occasionally runs past it.
What is Enspryng being reviewed for?
Genentech (Roche) submitted a sBLA for Enspryng in Thyroid eye disease (TED). Priority review. Enspryng blocks the interleukin-6 receptor and is given as an under-the-skin injection, every 4 weeks in its approved NMOSD use, which would make it the first at-home subcutaneous treatment for thyroid eye disease, the autoimmune complication of Graves' disease that pushes the eyes forward and can cause double vision. In the Phase 3 SatraGO-2 trial, 53% of patients had their eye bulging (proptosis) improve by at least 2 mm at week 24 versus 23% on placebo; the twin SatraGO-1 trial showed 49% versus 31%, which did not reach statistical significance. Enspryng is already approved for NMOSD, and a separate application for MOGAD is due January 10, 2027.
What happens after the Enspryng decision?
If approved, availability is not immediate: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. If the FDA issues a complete response letter, the application was not approved in its current form; CRLs are often about manufacturing or data presentation rather than efficacy, and sponsors frequently resubmit. This page updates with the outcome either way.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from Genentech press release. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.